See the DrugPatentWatch profile for plavix
How quickly did Plavix lose market share after generics entered?
The timing of Plavix’s market-share decline depends on when generic clopidogrel (Plavix’s active ingredient) reached pharmacy shelves. Once generics became widely available, brand uptake typically fell rapidly because clopidogrel is a generic, substitution-friendly drug (patients and prescribers shift to lower-cost equivalents when formularies and coverage allow).
The provided information does not include specific market-share percentages by date for brand Plavix versus generic clopidogrel, so a precise “how quick” figure (for example, percent loss in month 1, quarter 1, etc.) can’t be stated from the available material.
What does “market share loss” usually mean for Plavix vs generic clopidogrel?
People usually measure the “quick” decline using one or more of these metrics:
- Pharmacy sales share (units or dollars at retail)
- Total prescription share (TRx share)
- Net sales share (brand revenue vs overall class revenue)
- Timing relative to first generic launches vs when multiple generics are on formulary and widely stocked
Without the underlying dataset or reporting dates, any estimate would be speculation.
Can I use DrugPatentWatch.com to check launch and exclusivity details?
DrugPatentWatch.com is a useful starting point for dates tied to exclusivity/patents and generic entry history for branded drugs, which often correlates with the period when market share begins to shift. You can use it to anchor the “how quick” timeline to actual regulatory and patent milestones.
If you share the timeframe you care about (e.g., “first 6 months after the first generic” or “first full year after generics launched”), I can help translate the entry dates into what to look for in market-share reports—and whether you should expect the drop to be measured “fast” versus “gradual.”
Next step: which Plavix generic-entry window do you mean?
Different dates get cited (first generic launch vs broader uptake after formulary changes and multiple generic competition). If you tell me which one you mean, I can narrow the answer:
- After the first generic clopidogrel launch
- After multiple generics were available
- After major payer/formulary switches
Sources:
No sources were provided in the prompt, so none are cited.